Crohn's & Colitis Foundation Perspectives: IBD Review for Professionals
Optimizing Outcomes and Minimizing Risks of Therapies – Module 5

Jointly provided by the Crohn's & Colitis Foundation, RMEI Medical Education, LLC, and Postgraduate Institute for Medicine.

This activity is supported by independent educational grants from AbbVie and Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC.

Scroll to the Bottom of this Information to Begin this Course

Release date: December 18, 2017

Valid through: December 18, 2018

Specialty: Gastroenterology

Topic: IBD

Media: Internet

Estimated Time to Complete: 45 minutes

Target Audience

This activity is intended for gastroenterologists, gastroenterology nurse practitioners, and PAs who actively manage patients with inflammatory bowel disease (IBD), as well as managed care directors and hospital pharmacists interested in IBD treatment options.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize vaccine recommendations for adults with IBD
  • Discuss screening for bone density, colorectal, and cervical cancer in IBD patients
  • Apply preventative and therapeutic principles to optimize outcomes in IBD patients before, during, and after pregnancy

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)
  • Pharmacists0.75 contact hour(s) (0.075 CEUs)

All other healthcare professionals completing this course will be issued a statement of participation.


Meenakshi Bewtra, MD, MPH, PhD

Assistant Professor
Division of Gastroenterology
University of Pennsylvania School of Medicine
Philadelphia, PA

Joint Accreditation Statement

In support of improving patient care, these activities have been planned and implemented by the Postgraduate Institute for Medicine and Enquiring Minds. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-18-244-H01-P)

Type of Activity


Disclosures of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Meenakshi Bewtra, MD, MPH, PhD
  • Consulting fees: Janssen
  • Research: GlaxoSmithKline and Takeda Pharmaceuticals
  • Speaker’s Bureau: AbbVie

Postgraduate Institute for Medicine

Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP; have nothing to disclose.

Crohn's & Colitis Foundation
  • Sudha Sarode has no affiliations with commercial interests to disclose.
RMEI Medical Education, LLC
  • Faith Reidenbach has no affiliations with commercial interests to disclose.
  • Jessica Hatch has no affiliations with commercial interests to disclose.
  • Nora Hartley has no affiliations with commercial interests to disclose.

Fee Information

There is no fee for this educational activity.

Instructions for Obtaining Credit

During the period December 18, 2017 through December 18, 2018, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 60% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 59% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until you pass it successfully.

For Pharmacists: Upon successfully completing the post-test with a score of 60% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

Hardware and Software Requirements

FreeCME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks RealPlayer

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.